583 related articles for article (PubMed ID: 24048382)
1. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Sarafidis PA; Ruilope LM
Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H; Lazich I; Bakris GL
Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
[TBL] [Abstract][Full Text] [Related]
3. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
Rutkowski B; Tylicki L
J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
[TBL] [Abstract][Full Text] [Related]
4. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
[TBL] [Abstract][Full Text] [Related]
5. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
6. Dual renin-angiotensin system blockade for nephroprotection.
Ruggenenti P
Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
[TBL] [Abstract][Full Text] [Related]
7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
8. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
[TBL] [Abstract][Full Text] [Related]
9. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
[TBL] [Abstract][Full Text] [Related]
10. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
Wong J
Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
[TBL] [Abstract][Full Text] [Related]
11. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
Cohen DL; Townsend RR
J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
15. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
Leon SJ; Tangri N
Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
[TBL] [Abstract][Full Text] [Related]
16. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
17. The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design.
García-Prieto AM; Verdalles Ú; de José AP; Verde E; Arroyo D; Aragoncillo I; Linares T; Barbieri D; Goicoechea M
Hipertens Riesgo Vasc; 2020; 37(3):101-107. PubMed ID: 32156479
[TBL] [Abstract][Full Text] [Related]
18. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Feng YH; Fu P
Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
20. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.
El-Haddad B; Reule S; Drawz PE
Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
